Fusions of Breast Carcinoma and Dendritic Cells as a Vaccine for the Treatment of Metastatic Breast Cancer
Annual rept. 1 Jul 2003-30 Jun 2004
DANA-FARBER CANCER INST BOSTON MA
Pagination or Media Count:
The overall objective of this project is to study the safety, immunologic response and clinical effect of vaccinating breast cancer patients with dendritic cell DCtumor fusions in conjunction with IL-12. The hypothesis underlying these studies is that tumor specific immunity can be generated by the presentation of breast tumor antigens in the context of the potent antigen presenting machinery of the DC. Task 1 of the approved Statement of Work is to assess fusions of human breast carcinoma cells with autologous DC by evaluating cytokine production IL-12, IL-10 and potency of the fusions in generating tumor specific immunity in vitro Months 1-12. Our results demonstrate that fusions of breast cancer cells with immature or mature DC are associated with induction of phenotypic characteristics consistent with DC maturation and activation. The fusion cells express IL-12, IL-10 and the chemokine receptor CCR7. The breast tumorDC fusions were effective in stimulating i autologous T cell proliferation, ii cytokine production and iii tumor specific T cell responses. Based on these findings, our plan is to now perform the Phase III clinical trial of breast cancer cellDC fusions with IL-12 as a vaccine for patients with metastatic breast cancer Tasks 2-4 Protocol included in Appendix A.
- Medicine and Medical Research
- Anatomy and Physiology